Mariana C. Castells, MD, AAAAI 22: Indolent Systemic Mastocytosis and Monoclonal Mast Cell Activation Syndrome.

Effisayil 1 (NCT03782792) was a randomised, double-blind, placebo-controlled phase 2 study that investigated the efficacy and safety of spesolimab in generalized pustular psoriasis (GPP). touchIMMUNOLOGY were delighted to speak with Dr. Claudia De La Cruz (Clínica Dermacross, Santiago, Chile) to discuss the aims, design and findings from Effisayil 1 and the impact spesolimab has already […]

Pemphigus is a rare autoimmune blistering disease, which results in painful blisters on the skin or mucous membranes, severely impacting patient quality of life. It was a pleasure to talk with Prof. Dedee F. Murrell (St George Hospital Campus, Kogarah, Sydney, Australia) around the prevalence, clinical presentations and impact of pemphigus on patient quality of […]

The treatment paradigm for pemphigus remains with many unmet needs, the current standard of care remains to be systemic corticosteroids, which cause many phycological and metabolic side effects, in the past few years rituximab has been approved alongside steroids; however takes months to work. touchIMMUNOLOGY were delighted to talk with Prof. Dedee F. Murrell (St […]